The inherited cardiomyopathies, hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are relatively common, potentially life-threatening and currently untreatable. Mutations are often in the contractile proteins of cardiac muscle and cause abnormal Ca2+ regulation via troponin. HCM is usually linked to higher myofilament Ca2+-sensitivity whilst in both HCM and DCM mutant tissue there is often an uncoupling of the relationship between troponin I (TnI) phosphorylation by PKA and modulation of myofilament Ca2+-sensitivity, essential for normal responses to adrenaline. The adrenergic response is blunted, and this may predispose the heart to failure under stress. At present there are no compounds or interventions that can prevent or treat sarcomere cardiomyopathies. There is a need for novel therapies that act at a more fundamental level to affect the disease process. We demonstrated that epigallocatechin-3 gallate (EGCG) was found to be capable of restoring the coupled relationship between Ca2+-sensitivity and TnI phosphorylation in mutant thin filaments to normal in vitro, independent of the mutation (15 mutations tested). We have labeled this property "re-coupling." The action of EGCG in vitro to reverse the abnormality caused by myopathic mutations would appear to be an ideal pharmaceutical profile for treatment of inherited HCM and DCM but EGCG is known to be promiscuous in vivo and is thus unsuitable as a therapeutic drug. We therefore investigated whether other structurally related compounds can re-couple myofilaments without these off-target effects. We used the quantitative in vitro motility assay to screen 40 compounds, related to C-terminal Hsp90 inhibitors, and found 23 that can re-couple mutant myofilaments. There is no correlation between re-couplers and Hsp90 inhibitors. The Ca2+-sensitivity shift due to TnI phosphorylation was restored to 2.2 ± 0.01-fold (n = 19) compared to 2.0 ± 0.24-fold (n = 7) in wild-type thin filaments. Many of these compounds were either pure re-couplers or pure desensitizers, indicating these properties are independent; moreover, re-coupling ability could be lost with small changes of compound structure, indicating the possibility of specificity. Small molecules that can re-couple may have therapeutic potential. HIGHLIGHTS - Inherited cardiomyopathies are common diseases that are currently untreatable at a fundamental level and therefore finding a small molecule treatment is highly desirable.- We have identified a molecular level dysfunction common to nearly all mutations: uncoupling of the relationship between troponin I phosphorylation and modulation of myofilament Ca2+-sensitivity, essential for normal responses to adrenaline.- We have identified a new class of drugs that are capable of both reducing Ca2+-sensitivity and/or recouping the relationship between troponin I phosphorylation and Ca2+-sensitivity.- The re-coupling phenomenon can be explained on the basis of a single mechanism that is testable.- Measurements with a wide range of small molecules of varying structures can indicate the critical molecular features required for recoupling and allows the prediction of other potential re-couplers.

Department of Medicinal Chemistry The University of Kansas Lawrence KS United States

Laboratory of Biotransformation Institute of Microbiology of the Czech Academy of Sciences Prague Czechia

NHLI Imperial College London London United Kingdom

Zobrazit více v PubMed

Akkari P. A., Song Y., Hitchcock-DeGregori S., Blechynden L., Laing N. (2002). Expression and biological activity of Baculovirus generated wild-type human slow alpha tropomyosin and the Met9Arg mutant responsible for a dominant form of nemaline myopathy. Biochem. Biophys. Res. Commun. 296, 300–304. 10.1016/S0006-291X(02)00852-5 PubMed DOI

Baell J., Walters M. A. (2014). Chemistry: chemical con artists foil drug discovery. Nature 513, 481–483. 10.1038/513481a PubMed DOI

Bayliss C. R., Jacques A. M., Leung M.-C., Ward D. G., Redwood C. S., Gallon C. E., et al. (2012). Myofibrillar Ca2+-sensitivity is uncoupled from troponin i phosphorylation in hypertrophic obstructive cardiomyopathy due to abnormal troponin T. Cardiovasc. Res. 97, 500–508. 10.1093/cvr/cvs322 PubMed DOI

Biedermann D., Vavrikova E., Cvak L., Kren V. (2014). Chemistry of silybin. Nat. Prod. Rep. 31, 1138–1157. 10.1039/C3NP70122K PubMed DOI

Botten D., Fugallo G., Fraternali F., Molteni C. (2013). A computational exploration of the interactions of the green tea polyphenol (−)-epigallocatechin 3-gallate with cardiac muscle troponin C. PLoS ONE 8:e70556. 10.1371/annotation/23964dab-0e50-4644-b3b1-7c9e4ee09958 PubMed DOI PMC

Colson B. A., Gruber S. J., Thomas D. D. (2012). Structural dynamics of muscle protein phosphorylation. J. Muscle Res. Cell Motil. 33, 419–429. 10.1007/s10974-012-9317-6 PubMed DOI PMC

Dvornikov A. V., Smolin N., Zhang M., Martin J. L., Robia S. L., de Tombe P. P. (2016). Restrictive cardiomyopathy Troponin-I R145W mutation does not perturb myofilament length dependent activation in human cardiac sarcomeres. J Biol. Chem. 291, 21817–21828. 10.1074/jbc.M116.746172 PubMed DOI PMC

Dyer E., Jacques A., Hoskins A., Ward D., Gallon C., Messer A., et al. . (2009). Functional analysis of a unique troponin C mutation, Gly159Asp that causes familial dilated cardiomyopathy, studied in explanted heart muscle. Circ. Heart Fail. 2, 456–464. 10.1161/CIRCHEARTFAILURE.108.818237 PubMed DOI

Feng W., Hwang H. S., Kryshtal D. O., Yang T., Padilla I. T., Tiwary A. K., et al. . (2012). Coordinated regulation of murine cardiomyocyte contractility by Nanomolar (−)-Epigallocatechin-3-Gallate, the Major Green Tea Catechin. Mol. Pharmacol. 82, 993–1000. 10.1124/mol.112.079707 PubMed DOI PMC

Fraser I. D. C., Marston S. B. (1995). In vitro motility analysis of actin-tropomyosin regulation by troponin and Ca2+: the thin filament is switched as a single cooperative unit. J. Biol. Chem. 270, 7836–7841. 10.1074/jbc.270.14.7836 PubMed DOI

Friedrich F. W., Flenner F., Nasib M., Eschenhagen T., Carrier L. (2016). Epigallocatechin-3-Gallate Accelerates Relaxation and Ca2+ transient decay and desensitizes myofilaments in healthy and Mybpc3-targeted knock-in cardiomyopathic mice. Front. Physiol. 7:607. 10.3389/fphys.2016.00607 PubMed DOI PMC

Gažák R., Valentová K., Fuksová K., Marhol P., Kuzma M., Medina M. Á., et al. . (2011). Synthesis and antiangiogenic activity of new silybin galloyl esters. J. Med. Chem. 54, 7397–7407. 10.1021/jm201034h PubMed DOI

Gordon A. M., Homsher E., Regnier M. (2000). Regulation of contraction in striated muscle. Physiol. Rev. 80, 853–924. 10.1152/physrev.2000.80.2.853 PubMed DOI

Hall J. A., Forsberg L. K., Blagg B. S. (2014). Alternative approaches to Hsp90 modulation for the treatment of cancer. Future Med. Chem. 6, 1587–1605. 10.4155/fmc.14.89 PubMed DOI PMC

Hao H., Naomoto Y., Bao X., Watanabe N., Sakurama K., Noma K., et al. (2010). HSP90 and its inhibitors (Review). Oncol. Rep. 23, 1483–1492. 10.1158/1541-7786.MCR-15-0234 PubMed DOI

Hershberger R. E., Hedges D. J., Morales A. (2013). Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat. Rev. Cardiol. 10, 531–547. 10.1038/nrcardio.2013.105 PubMed DOI

Hwang P. M., Cai F., Pineda-Sanabria S. E., Corson D. C., Sykes B. D. (2014). The cardiac-specific N-terminal region of troponin I positions the regulatory domain of troponin C. Proc. Natl. Acad. Sci. U.S.A. 111, 14412–14417. 10.1073/pnas.1410775111 PubMed DOI PMC

Hwang P. M., Sykes B. D. (2015). Targeting the sarcomere to correct muscle function. Nat. Rev. Drug Discov. 14, 313–328. 10.1038/nrd4554 PubMed DOI

Ingólfsson H. I., Thakur P., Herold K. F., Hobart E. A., Ramsey N. B., Periole X., et al. . (2014). Phytochemicals perturb membranes and promiscuously alter protein function. ACS Chem. Biol. 9, 1788–1798. 10.1021/cb500086e PubMed DOI PMC

Kentish J. C., McCloskey D. T., Layland J., Palmer S., Leiden J. M., Martin A. F., et al. . (2001). Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle. Circ. Res. 88, 1059–1065. 10.1161/hh1001.091640 PubMed DOI

Khandelwal A., Hall J. A., Blagg B. S. J. (2013). Synthesis and Structure–Activity Relationships of EGCG Analogues, a Recently Identified Hsp90 Inhibitor. J. Org. Chem. 78, 7859–7884. 10.1021/jo401027r PubMed DOI PMC

Kren V., Walterová D. (2005). Silybin and silymarin–new effects and applications. Biomed. Pap. Med. Fac. Univ. Palacký Olomouc Czech Repub. 149, 29–41. 10.5507/bp.2005.002 PubMed DOI

Krenek K., Marhol P., Peikerov,á Ž., V K., Biedermann D. (2014). Preparatory separation of the silymarin flavonolignans by Sephadex LH-20 gel. Food Res. Int. 65, 115–120. 10.1016/j.foodres.2014.02.001 DOI

Lal S., Li A., Allen D., Allen P. D., Bannon P., Cartmill T., et al. . (2015). Best practice biobanking of human heart tissue. Biophys. Rev. 7, 399–406. 10.1007/s12551-015-0182-6 PubMed DOI PMC

Layland J., Solaro R. J., Shah A. M. (2005). Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc. Res. 66, 12–21. 10.1016/j.cardiores.2004.12.022 PubMed DOI

Lopes L. R., Elliott P. M. (2014). A straightforward guide to the sarcomeric basis of cardiomyopathies. Heart 100, 1916–1923. 10.1136/heartjnl-2014-305645 PubMed DOI

MacLeod K. T., Marston S. B., Poole-Wilson P. A., Severs N. J., Sugden P. H. (2010). Cardiac myocytes and the cardiac action potential, in Oxford Textbook of Medicine 5th edn, eds Warrel D. A., Cox T. M., Firth J. D. (Oxford: Oxford University Press; ), 2603-2617.

Marston S. (2016). Why is there a limit to the changes in myofilament Ca2+-sensitivity associated with myopathy causing mutations? Front. Physiol. 7:415. 10.3389/fphys.2016.00415 PubMed DOI PMC

Marston S. B., Fraser I. D. C., Wu B., Roper G. (1996). A simple method for automatic tracking of actin filaments in the motility assay. J. Musc. Res. Cell Motil. 17, 497–506. 10.1007/BF00123365 PubMed DOI

Marston S. B., Messer A. E., Eiros-Zamora J., Gould I., Papadaki M., Choudry A., et al. (2018). The molecular defects in Ca2+ regulation due to mutations that cause hypertrophic cardiomyopathy can be reversed by small molecules that bind to Troponin. Biophys. J. 114:37a 10.1016/j.bpj.2017.11.253 DOI

Marston S., Memo M., Messer A., Papadaki M., Nowak K., McNamara E., et al. . (2013). Mutations in repeating structural motifs of tropomyosin cause gain of function in skeletal muscle myopathy patients. Hum. Mol. Genet. 22, 4978–4987. 10.1093/hmg/ddt345 PubMed DOI PMC

Memo M., Leung M.-C., Ward D. G., dos Remedios C., Morimoto S., Zhang L., et al. (2013). Mutations in thin filament proteins that cause familial dilated cardiomyopathy uncouple Troponin I phosphorylation from changes in Myofibrillar Ca2+-sensitivity. Cardiovasc. Res. 99, 65–73. 10.1093/cvr/cvt071 PubMed DOI

Messer A., Bayliss C., El-Mezgueldi M., Redwood C., Ward D. G., Leung M.-C., et al. (2016). Mutations in troponin T associated with Hypertrophic Cardiomyopathy increase Ca2+-sensitivity and suppress the modulation of Ca2+-sensitivity by troponin I phosphorylation. Arch. Biochem. Biophys. 601, 113–120. 10.1016/j.abb.2016.03.027 PubMed DOI PMC

Messer A. E., Chan J., Daley A., Copeland O., Marston S. B., Connolly D. J. (2017). Investigations into the sarcomeric protein and Ca2+-regulation abnormalities underlying hypertrophic cardiomyopathy in cats (Felix catus). Front. Physiol. 8:348. 10.3389/fphys.2017.00348 PubMed DOI PMC

Messer A. E., Jacques A. M., Marston S. B. (2007). Troponin phosphorylation and regulatory function in human heart muscle: dephosphorylation of Ser23/24 on troponin I could account for the contractile defect in end-stage heart failure. J. Mol. Cell. Cardiol. 42, 247–259. 10.1016/j.yjmcc.2006.08.017 PubMed DOI

Messer A., Gallon C., McKenna W., Elliott P., Dos Remedios C., Marston S. (2009). The use of phosphate-affinity SDS-PAGE to measure the troponin I phosphorylation site distribution in human heart muscle. Proteomics Clin. Appl. 3, 1371–1382. 10.1002/prca.200900071 PubMed DOI

Messer A., Marston S. (2014). Investigating the role of uncoupling of Troponin I phosphorylation from changes in myofibrillar Ca2+-sensitivity in the pathogenesis of Cardiomyopathy. Front. Physiol. 5:315 10.3389/fphys.2014.00315 PubMed DOI PMC

Novotná M., Gažák R., Biedermann D., Di Meo F., Marhol P., Kuzma M., et al. (2014). cis– transIsomerization of silybins A and B. Beilstein J. Org. Chem. 10, 1047–1063. 10.3762/bjoc.10.105 PubMed DOI PMC

Papadaki M., Marston S. B. (2016). The importance of intrinsically disordered segments of cardiac troponin in modulating function by phosphorylation and disease-causing mutations. Front. Physiol. 7:735. 10.3389/fphys.2016.00508 PubMed DOI PMC

Papadaki M., Vikhorev P. G., Marston S. B., Messer A. E. (2015). Uncoupling of myofilament Ca2+ sensitivity from troponin I phosphorylation by mutations can be reversed by epigallocatechin-3-gallate. Cardiovasc. Res. 108, 99–110. 10.1093/cvr/cvv181 PubMed DOI PMC

Robertson I. M., Sun Y.-B., Li M. X., Sykes B. D. (2010). A structural and functional perspective into the mechanism of Ca2+-sensitizers that target the cardiac troponin complex. J. Mol. Cell. Cardiol. 49, 1031–1041. 10.1016/j.yjmcc.2010.08.019 PubMed DOI PMC

Robertson S. P., Johnson J. D., Holroyde M. J., Kranias E. G., Potter J. D., Solaro R. J. (1982). The effect of troponin I phosphorylation on the Ca2+-binding properties of the Ca2+-regulatory site of bovine cardiac troponin. J. Biol. Chem. 257, 260–263. PubMed

Singh B. N., Shankar S., Srivastava R. K. (2011). Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem. Pharmacol. 82, 1807–1821. 10.1016/j.bcp.2011.07.093 PubMed DOI PMC

Song W., Dyer E., Stuckey D., Copeland O., Leung M., Bayliss C., et al. . (2011). Molecular mechanism of the Glu99lys mutation in cardiac actin (ACTC gene) that causes apical hypertrophy in man and mouse. J. Biol. Chem. 286, 27582–27593. 10.1074/jbc.M111.252320 PubMed DOI PMC

Song W., Dyer E., Stuckey D., Leung M.-C., Memo M., Mansfield C., et al. . (2010). Investigation of a transgenic mouse model of familial dilated cardiomyopathy. J. Mol. Cell. Cardiol. 49, 380–389. 10.1016/j.yjmcc.2010.05.009 PubMed DOI

Song W., Vikhorev P. G., Kashyap M. N., Rowlands C., Ferenczi M. A., Woledge R. C., et al. . (2013). Mechanical and energetic properties of papillary muscle from ACTC E99K transgenic mouse models of hypertrophic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 304, H1513–H1524. 10.1152/ajpheart.00951.2012 PubMed DOI PMC

Tadano N., Du C., Yumoto F., Morimoto S., Ohta M., Xie M., et al. . (2010). Biological actions of green tea catechins on cardiac troponin C. Br. J. Pharmacol. 161, 1034–1043. 10.1111/j.1476-5381.2010.00942.x PubMed DOI PMC

Takeda N., Yamashita A., Maeda K., Maeda Y. (2003). Structure of the core domain of human cardiac troponin in the Ca2+-saturated form. Nature 424, 35–41. 10.1038/nature01780 PubMed DOI

Tardiff J. C., Carrier L., Bers D. M., Poggesi C., Ferrantini C., Coppini R., et al. . (2015). Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc. Res. 105, 457–470. 10.1093/cvr/cvv023 PubMed DOI PMC

Walsh R., Thomson K. L., Ware J. S., Funke B. H., Woodley J., McGuire K. J., et al. . (2017). Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet. Med. 19, 192–203. 10.1038/gim.2016.90 PubMed DOI PMC

Wilkinson R., Song W., Smoktunowicz N., Marston S. (2015). A dilated cardiomyopathy mutation blunts adrenergic response and induces contractile dysfunction under chronic angiotensin II stress. Am. J. Physiol. Heart Circ. Physiol. 309, H1936–H1946. 10.1152/ajpheart.00327.2015 PubMed DOI PMC

Zamora J. E., Hoben G., Sheehan A., Messer A., Chaudry A., Biedermann D., et al. (2017). EGCG and Silybin as treatment for inherited cardiomyopathies: binding simulations to cardiac troponin, in: 253rd, Conference: American Chemical Society National Meeting & Exposition.

Zamora J. E., Papadaki M., Messer A. E., Marston S. B., Gould I. R. (2016). Troponin structure: its modulation by Ca2+ and phosphorylation studied by molecular dynamics simulations. Phys. Chem. Chem. Phys. 18, 20691–20707. 10.1039/C6CP02610A PubMed DOI

Zhao H., Brandt G. E., Galam L., Matts R. L., Blagg B. S. J. (2011). Identification and initial SAR of silybin: an Hsp90 inhibitor. Bioorg. Med. Chem. Lett. 21, 2659–2664. 10.1016/j.bmcl.2010.12.088 PubMed DOI

Nutraceuticals silybin B, resveratrol, and epigallocatechin-3 gallate-bind to cardiac muscle troponin to restore the loss of lusitropy caused by cardiomyopathy mutations in vitro, in vivo, and in silico

Chirality Matters: Biological Activity of Optically Pure Silybin and Its Congeners